NewGenIvf Group Limited Class A Ordinary Shares Total Liabilities
NewGenIvf Group Limited Class A Ordinary Shares total liabilities. Based on the latest financial reports, NewGenIvf Group Limited Class A Ordinary Shares (NIVF) has total liabilities worth $6.74 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NewGenIvf Group Limited Class A Ordinary (NIVF) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of NewGenIvf Group Limited Class A Ordinary Shares (2021–2025)
Total liabilities of NewGenIvf Group Limited Class A Ordinary Shares from 2021 to 2025. This chart illustrates how NewGenIvf Group Limited Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Explore NIVF strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
NewGenIvf Group Limited Class A Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of NewGenIvf Group Limited Class A Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Digjam Limited
NSE:DIGJAMLTD
|
India | Rs765.44 Million |
|
Stinger Resources Inc
V:STNG
|
Canada | CA$5.35K |
|
Lucapa Diamond Co Ltd
F:NHY
|
Germany | €2.88 Million |
|
Candela Invest SA
BR:CAND
|
Belgium | €6.11 Million |
|
Global Battery Metals Ltd
V:GBML
|
Canada | CA$1.03 Million |
|
Clearside Biomedical Inc
NASDAQ:CLSD
|
USA | $65.59 Million |
|
Fonix Mobile plc
LSE:FNX
|
UK | GBX71.40 Million |
|
SRT Marine Systems plc
LSE:SRT
|
UK | GBX60.55 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down NewGenIvf Group Limited Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NIVF asset base.
Liquidity & Leverage Metrics
NewGenIvf Group Limited Class A Ordinary Shares Total Liabilities Ratios Explained
NewGenIvf Group Limited Class A Ordinary Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NewGenIvf Group Limited Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NewGenIvf Group Limited Class A Ordinary Shares (2021–2025)
The table below shows the annual total liabilities of NewGenIvf Group Limited Class A Ordinary Shares from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.74 Million | +33.14% |
| 2024-12-31 | $5.06 Million | -11.57% |
| 2023-12-31 | $5.72 Million | +104.04% |
| 2022-12-31 | $2.80 Million | +20.48% |
| 2021-12-31 | $2.33 Million | -- |
About NewGenIvf Group Limited Class A Ordinary Shares
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screen… Read more